FGFR2 and gastroesophageal junction adenocarcinoma: In our first case (46-year-old male with GEJ adenocarcinoma), molecular testing of both tissue and ctDNA identified FGFR2 amplification (plasma copy number 83.1) and a WDR11-AS1–FGFR2 fusion (2.4% VAF) was seen on ctDNA testing at disease progression.